Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial Pharmaceuticals (NASDAQ: ADIL) reported Q3 2024 financial results and business updates. The company achieved database lock for AD04's pharmacokinetics study in Alcohol Use Disorder (AUD) treatment. Cash position stood at $5.2 million as of September 30, 2024, expected to fund operations into H2 2025. Q3 net loss increased to $2.2 million from $1.4 million year-over-year. R&D expenses rose 399% due to clinical trial and CMC costs. The company partnered with Boudicca Dx for companion diagnostic development and secured new patent allowances.
Adial Pharmaceuticals (NASDAQ: ADIL) has appointed Vinay Shah as Chief Financial Officer, effective November 16, 2024. Shah brings over 25 years of experience in pharmaceutical and healthcare sectors, previously serving as CFO at Virpax Pharmaceuticals. His track record includes raising over $150 million at Aravive and contributing to Pacira Pharmaceuticals' IPO. The current CFO, Joseph Truluck, will resign on November 15, 2024, but will continue as a consultant through March 31, 2025, to ensure a smooth transition. Truluck's departure is not related to any disagreements with the company's operations or practices.
Adial Pharmaceuticals (NASDAQ: ADIL) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. CEO Cary Claiborne will deliver a presentation at 8:30 a.m. ET, and management will conduct one-on-one investor meetings throughout the day. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. Investors can register to attend and schedule meetings, with the presentation available via live stream.
Adial Pharmaceuticals (NASDAQ: ADIL) has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent. This patent will expand Adial's intellectual property protection for its lead investigational drug, AD04, designed to treat alcohol use disorder (AUD). The patent covers additional genotype combinations identified through the Company's proprietary genetic diagnostic tool, enhancing AD04's precision medicine approach.
Cary Claiborne, CEO of Adial Pharmaceuticals, stated that this milestone broadens their patent estate and provides greater flexibility in advancing AD04. He emphasized the company's commitment to delivering innovative, genetically-targeted treatments for addiction. The patent notification reinforces Adial's focus on using cutting-edge science to develop more effective treatments with fewer side effects for those affected by addiction.
Adial Pharmaceuticals (NASDAQ: ADIL) commends the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for its updated definition of recovery, which now includes non-abstinence solutions. This aligns with Adial's AD04 program for alcohol use disorder (AUD), which offers patients flexibility in reducing drinking and/or achieving abstinence.
The NIAAA's new definition, emphasized in its 2025 Professional Judgement Budget, recognizes that effective recovery solutions can focus on harm reduction and improved quality of life. This shift validates Adial's approach and potentially broadens its commercial and government market potential.
Cary Claiborne, CEO of Adial Pharmaceuticals, stated that AD04 is uniquely positioned to provide a therapeutic option for those seeking reduction in alcohol use or complete abstinence. The company is optimistic that NIAAA's new perspective will stimulate additional support for programs like AD04 in both commercial and government sectors.
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the database lock for its pharmacokinetics study of AD04, the company's lead investigational treatment for Alcohol Use Disorder (AUD) in heavy drinking patients. The study, which enrolled 30 healthy adult volunteers, compared the pharmacokinetic profile of AD04 at a 0.33 mg oral dose, with or without food, against a reference standard product.
Topline results are expected in the fourth quarter of 2024. The data has been transferred to independent statisticians for analysis, which will inform Adial's next FDA interaction and help shape the clinical strategy for the upcoming Phase 3 study. The company believes these results will strengthen its position for potential strategic collaborations and future clinical development of AD04.
Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on addiction treatment therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
CEO Cary Claiborne will represent Adial at the conference. The company's presentation will be available on-demand to registered attendees starting September 9, 2024, at 7:00 AM Eastern Time. Investors can access the presentation webcast through the conference platform or Adial's investor relations website.
Additionally, Adial's management team will be conducting one-on-one meetings with qualified investors throughout the conference. Interested parties can request meetings by contacting adil@crescendo-ir.com.
Adial Pharmaceuticals (NASDAQ: ADIL) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Initiated a pharmacokinetics study of AD04, their lead investigational drug for Alcohol Use Disorder (AUD), with topline results expected in Q4 2024.
2. Collaborated with Boudicca Dx to develop a companion diagnostic genetic test for AD04.
3. Filed a new patent application extending intellectual property protection to 2044.
4. Published two peer-reviewed articles supporting AD04's potential efficacy and safety profile.
5. Cash and cash equivalents were $3.3 million as of June 30, 2024.
6. Net loss was $2.5 million for Q2 2024, compared to a net income of $1.1 million in Q2 2023.
7. R&D expenses increased by $583,000 and G&A expenses increased by $228,000 compared to Q2 2023.
Adial Pharmaceuticals (NASDAQ: ADIL) has partnered with Boudicca Dx to advance the regulatory strategy for its companion diagnostic genetic test. This test is designed to accompany AD04, Adial's lead investigational asset for Alcohol Use Disorder (AUD) treatment. Boudicca Dx will support Adial in ensuring the test's compliance with FDA guidelines, a important step in Adial's regulatory strategy and preparation for its planned Phase 3 program.
The collaboration aims to validate the companion diagnostic both technically and clinically, supporting patient identification and recruitment for AD04 trials. This partnership is seen as a key component in Adial's mission to develop a first-in-class precision medicine for AUD treatment, addressing a significant unmet need in a disease affecting over 30 million people in the US and causing 3 million deaths worldwide annually.
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.
The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 mg oral dose, with or without food, against a reference standard. This milestone brings Adial closer to initiating their Phase 3 clinical trial and supports ongoing partnership discussions. The company plans to review the data thoroughly and engage with the FDA to align their development plan with regulatory expectations.